Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:33:44 ON 17 APR 2009

=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 11:34:01 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 APR 2009  HIGHEST RN 1135193-69-9
DICTIONARY FILE UPDATES:  15 APR 2009  HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> E "DMXAA"/CN 25
E1            1     DMX 400YB40RBK/CN
E2            1     DMX 7R/CN
E3            1 --> DMXAA/CN
E4            1     DMXAA SODIUM SALT/CN
E5            1     DMXAA-DICLOFENAC MIXTURE/CN
E6            1     DMXB-A/CN
E7            1     DMY PROTEIN (ORYZIAS CURVINOTUS GENE DMY)/CN
E8            1     DMZ/CN
E9            3     DN/CN
E10           1     DN (DISPERSANT)/CN
E11           1     DN (HUMAN PAPILLOMAVIRUS 35 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E12           1     DN (HUMAN PAPILLOMAVIRUS 39 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E13           1     DN (HUMAN PAPILLOMAVIRUS 44 GENE L1 244-NUCLEOTIDE FRAGMENT)/CN
E14           1     DN (HUMAN PAPILLOMAVIRUS 45 GENE L1 256-NUCLEOTIDE FRAGMENT)/CN
E15           1     DN (HUMAN PAPILLOMAVIRUS 51 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
```

```
E16          1     DN (HUMAN PAPILLOMAVIRUS 56 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E17          1     DN (HUMAN PAPILLOMAVIRUS 59 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E18          1     DN (HUMAN PAPILLOMAVIRUS 66 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E19          1     DN (HUMAN PAPILLOMAVIRUS 68 GENE L1 120-NUCLEOTIDE FRAGMENT)/CN
E20          1     DN (HUMAN PROTEIN SERINE/THREONINE KINASE GENE PLUS FLANKS)/CN
E21          1     DN (PESTICIDE)/CN
E22          2     DN 003/CN
E23          1     DN 0081/CN
E24          1     DN 02/CN
E25          1     DN 099/CN

=> S E3
L1           1 DMXAA/CN

=> DIS L1 1 SQIDE

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   117570-53-3  REGISTRY
CN   9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-  (CA INDEX NAME)
OTHER NAMES:
CN   5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid
CN   5,6-Dimethylxanthenone-4-acetic acid
CN   AS 1404
CN   DMXAA
CN   NSC 640488
CN   Vadimezan
MF   C17 H14 O4
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, CA,
       CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, EMBASE, IMSPATENTS,
       IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE,
       TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Conference; Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PROC
       (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); PREP (Preparation); PROC (Process); PRP (Properties); USES
       (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  BIOL (Biological
       study); FORM (Formation, nonpreparative)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             189 REFERENCES IN FILE CA (1907 TO DATE)
```

```
              4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            189 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> E "GEMCITABINE"/CN 25
E1          1     GEMCADIOL/CN
E2          1     GEMCAT 200/CN
E3          1 --> GEMCITABINE/CN
E4          1     GEMCITABINE 5'-DIPHOSPHATE/CN
E5          1     GEMCITABINE HYDROCHLORIDE/CN
E6          1     GEMCITABINE TRIPHOSPHATE/CN
E7          1     GEMCO/CN
E8          1     GEMEDINE/CN
E9          1     GEMEDIS/CN
E10         1     GEMEPROST/CN
E11         1     GEMETREL/CN
E12         1     GEMEX/CN
E13         1     GEMEX AGENT 03/CN
E14         1     GEMFIBROZIL/CN
E15         1     GEMFIBROZIL 1-O-B-D-GLUCURONIDE/CN
E16         1     GEMFIBROZIL GLUCURONIDE/CN
E17         1     GEMFIBROZIL POTASSIUM SALT/CN
E18         1     GEMFIBROZIL SODIUM SALT/CN
E19         1     GEMFIBROZIL-VITAMIN B6 MIXTURE/CN
E20         1     GEMFLEX 1031C/CN
E21         1     GEMFLEX 307/CN
E22         1     GEMFLEX 409/CN
E23         1     GEMGEL 100/CN
E24         1     GEMGEL 100+/CN
E25         1     GEMICHALCONE A/CN

=> S E3
L2          1 GEMCITABINE/CN

=> DIS L2 1 SQIDE

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   95058-81-4  REGISTRY
CN   Cytidine, 2'-deoxy-2',2'-difluoro-  (CA INDEX NAME)
OTHER NAMES:
CN   2',2'-Difluoro-2'-deoxycytidine
CN   2',2'-Difluorodeoxycytidine
CN   2'-Deoxy-2',2'-difluorocytidine
CN   DDFC
CN   DFdC
CN   DFdCyd
CN   Folfugem
CN   Gamcitabine
CN   Gemcitabine
CN   LY 188011
CN   NSC 613327
FS   STEREOSEARCH
MF   C9 H11 F2 N3 O4
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, HSDB*,
       IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC,
       PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
       USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent
```

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4554 REFERENCES IN FILE CA (1907 TO DATE)
89 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4594 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.76	15.98

FILE 'MEDLINE' ENTERED AT 11:34:54 ON 17 APR 2009

FILE 'CAPLUS' ENTERED AT 11:34:54 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:34:54 ON 17 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:34:54 ON 17 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
L3 370 L1

=> s l2
L4 5732 L2

=> s l3 and l4
L5 13 L3 AND L4

=> d l5 1-13 ibib, abs, hitstr

L5 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1250046 CAPLUS
DOCUMENT NUMBER: 149:448110
TITLE: Preparation of Iso CA-4 and analogs as potent cytotoxic agents and inhibitors of polymerization of tubulin
INVENTOR(S): Alami, Mouad; Brion, Jean-Daniel; Provot, Olivier; Peyrat, Jean-Francois; Messaoudi, Samir; Hamze, Abdallah; Giraud, Anne; Bignon, Jerome; Bakala, Joanna; Liu, Jian-Miao
PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.
SOURCE: PCT Int. Appl., 78pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122620	A1	20081016	WO 2008-EP54118	20080404
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2914640	A1	20081010	FR 2007-54280	20070404
PRIORITY APPLN. INFO.:			FR 2007-54280 A	20070404
OTHER SOURCE(S):	MARPAT 149:448110			

GI



I



II



III

AB Isocombretastatin A-4 and analogs I [R1, R2, R3 = methoxy (possibly substituted by one or more fluorine atoms); R5 = R6 = hydrogen or fluorine; A = ring chosen from (un)substituted aryls and heteroaryls]. The process for the preparation of I comprises: (a) reaction of acetophenone derivative II with an organometallic compound, A-M [M = alkali metal or earth alkaline metal substituted with a halogen]; and (b) reaction of the resulting phenylethanol derivative III with an acid to form I. Thus, Iso-CA-4 [I; A =

C6H3OH-3-OMe-4, R1 = R2 = R3 = OMe, R4 = R5 = R6 = H (IV)] was prepared from 3,4,5-trimethoxyacetophenone (II; R1 = R2 = R3 = OMe, R4 = R5 = R6 = H) via reaction in PhMe with tert-butyl(5-lithio-2-methoxyphenoxy)dimethylsilane [prepared from tert-butyl(5-iodo-2-methoxyphenoxy)dimethylsilane via lithiation with Me3CLi in hexane], dehydration of III with p-toluenesulfonic acid in CH2Cl2, and desilylation with K2CO3 in MeOH. The cytotoxic activity of IV was determined [IC50 = 2-4 nM vs. HCT116; IC50 = 5 nM vs. K562 cells; IC50 = 2 nM vs. B16F10 cells; IC50 = 8 nM vs. U87 cells; IC50 = 8 nM vs. A549 cells; IC50 = 4.5 nM vs. M435 cells; IC50 = 4 nM vs. M231 cells; IC50 = 2.2 μM vs tubulin polymerization].

IT 95058-81-4, Gemcitabine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination chemotherapy antitumor agent; iso CA-4 and analogs as powerful cytotoxic agents and inhibitors of tubulin polymerization)

RN 95058-81-4 CAPLUS

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, DMXAA
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(reaction of, with iso CA-4 and aminodeoxy-iso-CA-4; iso CA-4 and analogs as powerful cytotoxic agents and inhibitors of tubulin polymerization)

RN 117570-53-3 CAPLUS

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:473431 CAPLUS

DOCUMENT NUMBER: 148:463206

TITLE: oncolytic viruses and antiangiogenic agents in the treatment of cancer

INVENTOR(S): Karrasch, Matthias; Mescheder, Axel

PATENT ASSIGNEE(S): Medigene AG, Germany

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008043576	A1	20080417	WO 2007-EP8930	20071015

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-851598P P 20061013

AB The invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy. Intraarterial infusions of oncolytic virus NV1020 to a patient with progressive metastatic colorectal adenocarcinoma followed by CPT-11 plus cetuximab resulted in stabilization of the disease at 6 mo post treatment.

IT 117570-53-3, DMXAA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oncolytic viruses and antiangiogenic agents in treatment of cancer)

RN 117570-53-3 CAPLUS

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



IT 95058-81-4, Gemcitabine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oncolytic viruses and antiangiogenic agents in treatment of cancer)

RN 95058-81-4 CAPLUS

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:984120 CAPLUS
DOCUMENT NUMBER: 143:279360
TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor
INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan Johannes Jacobus; Voest, Emile Eugene; Beerepoot, Laurens Victor; Mehra, Niven
PATENT ASSIGNEE(S): Primagen Holding B. V., Neth.; UMC Utrecht Holding B. V.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
EP 1725679	A1	20061129	EP 2005-710924	20050302
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070077578	A1	20070405	US 2006-514345	20060831
US 20090098563	A1	20090416	US 2008-284203	20080919
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			EP 2005-710924	A 20050302
			WO 2005-NL155	W 20050302
			US 2006-514345	B1 20060831

AB This invention provides methods of detecting CD133 antigen (AC133)

expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.

IT 95058-81-4, Gemcitabine 117570-53-3, DMXAA
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor)

RN 95058-81-4 CAPLUS
CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 117570-53-3 CAPLUS
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2005:975665 CAPLUS
DOCUMENT NUMBER:	143:264929
TITLE:	Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases
INVENTOR(S):	Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene
PATENT ASSIGNEE(S):	Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.
SOURCE:	Eur. Pat. Appl., 28 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725679	A1	20061129	EP 2005-710924	20050302
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			WO 2005-NL155	W 20050302

AB The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jegher's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.

IT 95058-81-4, Gemcitabine 117570-53-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases)

RN 95058-81-4 CAPLUS

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 117570-53-3 CAPLUS

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:202462 CAPLUS
DOCUMENT NUMBER: 138:226761
TITLE: Synergistic anticancer combinations containing 5,6-dimethylxanthenone-4-acetic acid
INVENTOR(S): Wilson, William Robert; Siim, Bronwyn Gae
PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020259	A2	20030313	WO 2002-GB4025	20020903
WO 2003020259	A3	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2458459	A1	20030313	CA 2002-2458459	20020903
AU 2002324143	A1	20030318	AU 2002-324143	20020903
AU 2002324143	B2	20070913		
EP 1423105	A2	20040602	EP 2002-758562	20020903
EP 1423105	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012258	A	20041019	BR 2002-12258	20020903
JP 2005509599	T	20050414	JP 2003-524567	20020903
CN 1708296	A	20051214	CN 2002-817257	20020903
NZ 531045	A	20060831	NZ 2002-531045	20020903
EP 1759694	A2	20070307	EP 2006-77049	20020903
EP 1759694	A3	20090218		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
NZ 546573	A	20070531	NZ 2002-546573	20020903
CN 1994287	A	20070711	CN 2006-10151393	20020903
NZ 554093	A	20080731	NZ 2002-554093	20020903
AT 415963	T	20081215	AT 2002-758562	20020903
NO 2004000591	A	20040430	NO 2004-591	20040210

ZA	2004001078	A	20050415	ZA	2004-1078	20040210
US	20040204480	A1	20041014	US	2004-790943	20040302
MX	2004002004	A	20050217	MX	2004-2004	20040302
IN	2004CN00684	A	20060113	IN	2004-CN684	20040402
US	20070060637	A1	20070315	US	2006-592678	20061103
AU	2007202083	A1	20070531	AU	2007-202083	20070509
US	20080070847	A1	20080320	US	2007-830650	20070730
US	20080070848	A1	20080320	US	2007-830659	20070730
US	20080070886	A1	20080320	US	2007-830668	20070730
US	20080070849	A1	20080320	US	2007-830677	20070730
PRIORITY APPLN. INFO.:				GB	2001-21285	A 20010903
				AU	2002-324143	A3 20020903
				CN	2002-817257	A3 20020903
				EP	2002-758562	A3 20020903
				WO	2002-GB4025	W 20020903
				US	2004-790943	A1 20040302

AB The present invention relates to synergistic combinations of the 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compds., Vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have antitumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compds. containing the combinations. The antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations was assessed by varying the dose of chemotherapeutic drug up to the toxicity limit, with co-administration of a fixed DMXAA dose (80 μmol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay. Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil, cyclophosphamide and cisplatin) had appreciable activity against this tumor as indicated by dose-response relationships providing significant slopes by linear regression, and highly significant growth delays of 10 days at their MTDs.

IT 95058-81-4, Gemcitabine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic anticancer combinations)

RN 95058-81-4 CAPLUS

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)

RN 117570-53-3 CAPLUS

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2008:80755 USPATFULL
TITLE: ANTI-CANCER COMBINATIONS
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND
Siim, Bronwyn G., Auckland, NEW ZEALAND
PATENT ASSIGNEE(S): CANCER RESEARCH TECHNOLOGY LIMITED, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070886	A1	20080320
APPLICATION INFO.:	US 2007-830668	A1	20070730 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 95058-81-4, Gemcitabine
(synergistic anticancer combinations)
RN 95058-81-4 USPATFULL
CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



```
=> d his

     (FILE 'HOME' ENTERED AT 11:33:44 ON 17 APR 2009)

     FILE 'REGISTRY' ENTERED AT 11:34:01 ON 17 APR 2009
                E "DMXAA"/CN 25
L1            1 S E3
                E "GEMCITABINE"/CN 25
L2            1 S E3

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:34:54 ON 17 APR
     2009
L3          370 S L1
L4         5732 S L2
L5           13 S L3 AND L4

=> s l3 and antimetabolite
L6            8 L3 AND ANTIMETABOLITE

=> d l6 1-8 ibib, abs, hitstr

L6   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2004:284727  CAPLUS
DOCUMENT NUMBER:          142:85467
TITLE:                    The Cancer Research UK experience of pre-clinical
                          toxicology studies to support early clinical trials
                          with novel cancer therapies
AUTHOR(S):                Newell, D. R.; Silvester, J.; McDowell, C.; Burtles,
                          S. S.
CORPORATE SOURCE:         Cancer Research UK, Drug Development Office, London,
                          WC2A 3PX, UK
SOURCE:                   European Journal of Cancer (2004), 40(6), 899-906
                          CODEN: EJCAEL; ISSN: 0959-8049
PUBLISHER:                Elsevier Science Ltd.
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
AB   A review.  Pre-clin. toxicol. studies in rodents and Phase I clin. trial
     data are summarized for 14 novel anticancer therapies.  With only one
     exception, an antifolate antimetabolite, rodent toxicol.
     predicted a safe Phase I trial starting dose and the majority of the dose
     limiting toxicities, in particular haematol. toxicity.  For targeted
     agents with well-defined pharmacodynamic markers, illustrated in the
     current study by 3 anti-endocrine drugs and one resistance modifier, the
     definition of a maximum tolerated dose can be avoided.  Together with earlier
     data, the current study confirms that pre-clin. toxicol. studies in a
     non-rodent species are not routinely needed for the safe conduct of early
     clin. trials with new cancer chemotherapies.
```

IT 117570-53-3, DMXAA
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer research UK experience of pre-clin. toxicol. studies to support early clin. trials with novel cancer therapies)
RN 117570-53-3 CAPLUS
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 USPATFULL on STN

ACCESSION NUMBER:	2008:80755 USPATFULL
TITLE:	ANTI-CANCER COMBINATIONS
INVENTOR(S):	Wilson, William R., Waiuku, NEW ZEALAND Siim, Bronwyn G., Auckland, NEW ZEALAND
PATENT ASSIGNEE(S):	CANCER RESEARCH TECHNOLOGY LIMITED, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070886	A1	20080320
APPLICATION INFO.:	US 2007-830668	A1	20070730 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	1275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods

of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
RN 117570-53-3 USPATFULL
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 11:33:44 ON 17 APR 2009)

     FILE 'REGISTRY' ENTERED AT 11:34:01 ON 17 APR 2009
                E "DMXAA"/CN 25
L1             1 S E3
                E "GEMCITABINE"/CN 25
L2             1 S E3

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:34:54 ON 17 APR
     2009
L3           370 S L1
L4          5732 S L2
L5            13 S L3 AND L4
L6             8 S L3 AND ANTIMETABOLITE

=> s l3 and (?potentiat? or ?enhanc? or ?increas?)
L7          228 L3 AND (?POTENTIAT? OR ?ENHANC? OR ?INCREAS?)

=> s l7 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)
L8          224 L7 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

=> s l8 and (pd<20020903 or prd<20020903)
'20020903' NOT A VALID FIELD CODE
   2 FILES SEARCHED...
   3 FILES SEARCHED...
L9          132 L8 AND (PD<20020903 OR PRD<20020903)

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10          83 DUP REM L9 (49 DUPLICATES REMOVED)

=> s l10 and antimetabolite
L11           6 L10 AND ANTIMETABOLITE

=> d l6 1-11 ibib, abs, hitstr

L6   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2004:284727  CAPLUS
```

DOCUMENT NUMBER: 142:85467
TITLE: The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies
AUTHOR(S): Newell, D. R.; Silvester, J.; McDowell, C.; Burtles, S. S.
CORPORATE SOURCE: Cancer Research UK, Drug Development Office, London, WC2A 3PX, UK
SOURCE: European Journal of Cancer (2004), 40(6), 899-906
CODEN: EJCAEL; ISSN: 0959-8049
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Pre-clin. toxicol. studies in rodents and Phase I clin. trial data are summarized for 14 novel anticancer therapies. With only one exception, an antifolate antimetabolite, rodent toxicol. predicted a safe Phase I trial starting dose and the majority of the dose limiting toxicities, in particular haematol. toxicity. For targeted agents with well-defined pharmacodynamic markers, illustrated in the current study by 3 anti-endocrine drugs and one resistance modifier, the definition of a maximum tolerated dose can be avoided. Together with earlier data, the current study confirms that pre-clin. toxicol. studies in a non-rodent species are not routinely needed for the safe conduct of early clin. trials with new cancer chemotherapies.

IT 117570-53-3, DMXAA
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer research UK experience of pre-clin. toxicol. studies to support early clin. trials with novel cancer therapies)

RN 117570-53-3 CAPLUS
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2008:80755 USPATFULL
TITLE: ANTI-CANCER COMBINATIONS
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND
Siim, Bronwyn G., Auckland, NEW ZEALAND
PATENT ASSIGNEE(S): CANCER RESEARCH TECHNOLOGY LIMITED, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070886	A1	20080320
APPLICATION INFO.:	US 2007-830668	A1	20070730 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

NUMBER DATE

PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)

RN 117570-53-3 USPATFULL

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:33:44 ON 17 APR 2009)

FILE 'REGISTRY' ENTERED AT 11:34:01 ON 17 APR 2009

		E	"DMXAA"/CN 25
L1	1	S	E3
		E	"GEMCITABINE"/CN 25
L2	1	S	E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:34:54 ON 17 APR 2009

L3	370	S	L1
L4	5732	S	L2
L5	13	S	L3 AND L4
L6	8	S	L3 AND ANTIMETABOLITE

```
L7          228 S L3 AND (?POTENTIAT? OR ?ENHANC? OR ?INCREAS?)
L8          224 S L7 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)
L9          132 S L8 AND (PD<20020903 OR PRD<20020903)
L10          83 DUP REM L9 (49 DUPLICATES REMOVED)
L11           6 S L10 AND ANTIMETABOLITE

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    103.87     119.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -5.74      -5.74

STN INTERNATIONAL LOGOFF AT 11:39:17 ON 17 APR 2009
```